Belimumab May Reduce Organ Damage in SLE, Lupus Nephritis
Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator.
Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator.
Adverse effects of induction therapies for lupus nephritis may limit their use.
Proteinuria and estimated glomerular filtration rate cannot accurately distinguish between ongoing inflammatory injury and chronic kidney damage in lupus nephritis, investigators pointed out.
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
Researchers developed a consensus-based standardized corticosteroid dosing regimen for patients with childhood-onset systemic lupus erythematosus with lupus nephritis.
Study authors suggest future research assess the potential benefits of screening COVID-19 patients for antiphospholipids and other autoantibodies
Although studies support the clinical benefits of belimumab and voclosporin, their cost-effectiveness has not been established.
The board of the Immunonephrology Working Group of the European Renal Association reviewed 2 recent guidelines to establish if and how some of the differences may affect clinical practice.
Nephrotoxicity remains a major concern with the use of calcineurin inhibitors.
Researchers assessed molecular changes of Tr1 cells through CD46 cytoplasmic tail in patients with lupus nephritis who received intravenous methylprednisone therapy.